Dexamethasone‐loaded β‐cyclodextrin for osteogenic induction of mesenchymal stem/progenitor cells and bone regeneration
- 27 September 2020
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 109 (7) , 1125-1135
Abstract
Dexamethasone (DEX) is a glucocorticoid commonly used as an in vitro osteogenic inducer of mesenchymal stem/progenitor cells (abbreviated MSCs). However, several studies investigating the effects of glucocorticoids on bone regeneration through systemic injections have demonstrated negative impacts of the drugs at high concentration on the healing of hard tissues. These contrasting evidences suggest that application of glucocorticoids should be limited to low dosages but at the same time a long enough treatment period is preferred, which prompted us to evaluate the effects of different local release systems of DEX on MSC differentiation and bone repair. Two types of DEX‐loaded β‐cyclodextrin (CD) complexes, including CD/DEX and CD/AD‐DEX, were fabricated via host‐guest interactions and characterized by FTIR, 1H‐NMR, MS‐ESI, and UV–vis. The results demonstrated that these CD‐based assemblies released DEX in differentiated profiles, with CD/DEX releasing significantly faster than CD/AD‐DEX. Although CD/DEX were slightly more powerful than CD/AD‐DEX in inducing rat bone marrow MSCs (rBMSCs) into osteogenic lineage in vitro, CD/AD‐DEX was advantageous over CD/DEX in accelerating bone regeneration over a time period of 4 weeks in a rat tibia defect model. The results suggest that DEX‐loaded assemblies via host‐guest interactions are flexible in modulating DEX release patterns and have great potential in bone tissue engineering.Keywords
Funding Information
- Department of Science and Technology of Hunan Province (2017JJ3421, 2018SK2106)
- National Natural Science Foundation of China (31670997, 81900982)
This publication has 46 references indexed in Scilit:
- Perioperative glucocorticosteroid treatment delays early healing of a mandible wound by inhibiting osteogenic differentiationInjury, 2012
- Sp1-dependent Activation of HDAC7 Is Required for Platelet-derived Growth Factor-BB-induced Smooth Muscle Cell Differentiation from Stem CellsJournal of Biological Chemistry, 2010
- Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defectsBiomaterials, 2010
- Starch-poly-є-caprolactone Microparticles Reduce the Needed Amount of BMP-2Clinical Orthopaedics and Related Research, 2009
- Preparation and characterization of starch-poly-ε-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applicationsActa Biomaterialia, 2009
- Three‐dimensional fibrous PLGA/HAp composite scaffold for BMP‐2 deliveryBiotechnology and Bioengineering, 2007
- Perioperative dexamethasone reduces post-surgical sequelae of wisdom tooth removal. A split-mouth randomized double-masked clinical trialInternational Journal of Oral and Maxillofacial Surgery, 2006
- Effects of short‐term treatment with systemic prednisone on bone healing: an experimental study in ratsDental Traumatology, 2005
- Innovations in Oligonucleotide Drug DeliveryJournal of Pharmaceutical Sciences, 2003
- Effect of the Hydrophobic Nature of Triacetyl-.BETA.-cyclodextrin on the Complexation with Nicardipine Hydrochloride: Physicochemical and Dissolution Properties of the Kneaded and Spray-dried Complexes.Chemical and Pharmaceutical Bulletin, 2002